⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21557059 | 1.00 | — | — | |
| SCHEMBL26903206 | 1.00 | — | — | |
| SCHEMBL8053694 | 1.00 | — | — | |
| SCHEMBL5689671 | 1.00 | — | — | |
| SCHEMBL19854893 | 1.00 | — | — | |
| SCHEMBL8675050 | 0.82 | TP53 (0.44) | — | |
| SCHEMBL8395798 | 0.80 | — | — | |
| SCHEMBL276441 | 0.76 | — | — | |
| SCHEMBL7530284 | 0.76 | LMNA (0.38) | — | |
| SCHEMBL12868869 | 0.76 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023102507-A1 | MACROCYCLIC IMMUNOMODULATORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2023-06-08 | — | — | WO | disclosed |
| WO-2022245759-A2 | AGENTS FOR DIRECTED CONJUGATION TECHNIQUES AND CONJUGATED PRODUCTS | BIOHAVEN THERAPEUTICS LTD. (US) | 2022-11-24 | — | — | WO | disclosed |
| WO-2022246086-A1 | ANTIBODY DRUG CONJUGATES USING MATES TECHNOLOGY FOR DELIVERING CYTOTOXIC AGENTS | BIOHAVEN THERAPEUTICS LTD. (US) | 2022-11-24 | — | — | WO | disclosed |
| US-11306125-B2 | PCSK9 antagonists bicyclo-compounds | MERCK SHARP & DOHME CORP. (US) | 2022-04-19 | — | — | US | disclosed |
| WO-2021195401-A1 | TECHNOLOGIES FOR PREVENTING OR TREATING INFECTIONS | BIOHAVEN THERAPEUTICS LTD. (US) | 2021-09-30 | — | — | WO | disclosed |
| US-20210214395-A1 | PCSK9 ANTAGONISTS BICYCLO-COMPOUNDS | MERCK SHARP & DOHME LLC | 2021-07-15 | — | — | US | disclosed |
| WO-2021133643-A1 | STAPLED OLEFIN CO-AGONISTS OF THE GLUCAGON AND GLP-1 RECEPTORS | MERCK SHARP & DOHME CORP. (US) | 2021-07-01 | — | — | WO | disclosed |
| EP-3842449-A1 | STAPLED OLEFIN CO-AGONISTS OF THE GLUCAGON AND GLP-1 RECEPTORS | MERCK SHARP & DOHME CORP. (US) | 2021-06-30 | — | — | EP | disclosed |
| US-20210147484-A1 | BICYCLIC PEPTIDE LIGANDS AND USES THEREOF | BICYCLETX LIMITED (GB) | 2021-05-20 | — | — | US | disclosed |
| US-10961189-B2 | Spiro-lactam NMDA receptor modulators and uses thereof | APTINYX INC. (US) | 2021-03-30 | — | — | US | disclosed |
| WO-2019152681-A1 | SPIRO-LACTAM AND BIS-SPIRO-LACTAM NMDA RECEPTOR MODULATORS AND USES THEREOF | APTINYX INC. (US) | 2019-08-08 | — | — | WO | disclosed |
| WO-2019152696-A1 | SPIRO-LACTAM NMDA RECEPTOR MODULATORS AND USES THEREOF | APTINYX INC. (US) | 2019-08-08 | — | — | WO | disclosed |
| US-20190161442-A1 | SPIRO-LACTAM NMDA RECEPTOR MODULATORS AND USES THEREOF | TENACIA BIOTECHNOLOGY (HONG KONG) CO., LIMITED (HK) | 2019-05-30 | — | — | US | disclosed |
| US-20180127430-A1 | SPIRO-LACTAM NMDA RECEPTOR MODULATORS AND USES THEREOF | TENACIA BIOTECHNOLOGY (HONG KONG) CO., LIMITED (HK) | 2018-05-10 | — | — | US | disclosed |
| US-20180127430-A1 | SPIRO-LACTAM NMDA RECEPTOR MODULATORS AND USES THEREOF | TENACIA BIOTECHNOLOGY (HONG KONG) CO., LIMITED (HK) | 2018-05-10 | — | — | US | disclosed |
| US-9708335-B2 | Spiro-lactam NMDA receptor modulators and uses thereof | Apytinyx Inc. (US) | 2017-07-18 | — | — | US | disclosed |
| US-20150368254-A1 | SPIRO-LACTAM NMDA RECEPTOR MODULATORS AND USES THEREOF | TENACIA BIOTECHNOLOGY (HONG KONG) CO., LIMITED (HK) | 2015-12-24 | — | — | US | disclosed |